- Home
- PNFP vs VRNA Comparison
PNFP vs VRNA Comparison
Compare PNFP & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNFP
- VRNA
- Stock Information
- Founded
- PNFP 2000
- VRNA 2005
- Country
- PNFP United States
- VRNA United Kingdom
- Employees
- PNFP N/A
- VRNA N/A
- Industry
- PNFP Major Banks
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- PNFP Finance
- VRNA Health Care
- Exchange
- PNFP Nasdaq
- VRNA Nasdaq
- Market Cap
- PNFP 7.0B
- VRNA 8.3B
- IPO Year
- PNFP N/A
- VRNA 2017
- Fundamental
- Price
- PNFP $93.36
- VRNA $106.79
- Analyst Decision
- PNFP Buy
- VRNA Buy
- Analyst Count
- PNFP 13
- VRNA 11
- Target Price
- PNFP $115.62
- VRNA $114.10
- AVG Volume (30 Days)
- PNFP 1.1M
- VRNA 1.5M
- Earning Date
- PNFP 10-15-2025
- VRNA 11-03-2025
- Dividend Yield
- PNFP 1.03%
- VRNA N/A
- EPS Growth
- PNFP 48.26
- VRNA N/A
- EPS
- PNFP 7.51
- VRNA N/A
- Revenue
- PNFP $1,812,787,000.00
- VRNA $221,673,000.00
- Revenue This Year
- PNFP $29.38
- VRNA $909.96
- Revenue Next Year
- PNFP $12.10
- VRNA $76.47
- P/E Ratio
- PNFP $12.43
- VRNA N/A
- Revenue Growth
- PNFP 21.56
- VRNA N/A
- 52 Week Low
- PNFP $81.57
- VRNA $29.26
- 52 Week High
- PNFP $131.91
- VRNA $106.86
- Technical
- Relative Strength Index (RSI)
- PNFP 41.38
- VRNA 70.44
- Support Level
- PNFP $91.28
- VRNA $105.78
- Resistance Level
- PNFP $96.50
- VRNA $106.86
- Average True Range (ATR)
- PNFP 2.19
- VRNA 0.16
- MACD
- PNFP -0.32
- VRNA -0.05
- Stochastic Oscillator
- PNFP 26.70
- VRNA 93.52
About PNFP Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.